search
Back to results

Macronutrient Regulation of Ghrelin and Peptide YY

Primary Purpose

Obesity, Prader Willi Syndrome

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
High carbohydrate meal
High fat meal
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Obesity focused on measuring Obesity, Orexigen, Insulin, Leptin, Adiponectin, Growth hormone replacement

Eligibility Criteria

5 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Diagnosis of PWS confirmed by chromosome analysis (i.e. interstitial deletion of paternally-derived chromosome 15Q, uniparental maternal disomy or other chromosome 15 abnormalities) or normal control
  2. Subjects with simple obesity
  3. Ages 5 years to 17 years
  4. Written informed consent and assent obtained and willingness to comply with the study schedule and procedures.
  5. Free T4, TSH values in the normal range (either endogenous or with thyroxine replacement)

Exclusion Criteria:

  1. Patients with any other clinically significant disease that would have an impact on body composition including diabetes mellitus, chronic inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders
  2. Concomitant use of an investigational drug in the past year
  3. Patients with an active malignancy
  4. Parent or legal guardian unable to provide informed consent.

Sites / Locations

  • Duke University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Healthy obese children

Children with Prader Willi Syndrome

Arm Description

High carbohydrate meal High fat meal

High carbohydrate meal High fat meal

Outcomes

Primary Outcome Measures

Change in ghrelin levels
The change in ghrelin levels will be measured before and after meal consumption in children with PWS, and healthy obese controls. Following an overnight 8 hour fast, subjects will be given either a high carbohydrate or high fat meal. Subjects will be allowed 25 minutes to consume everything on their food tray. Blood samples will be obtained before the meal (fasting) and every 30 minutes thereafter for 4 hours.
Change in PYY concentrations
The change in PYY concentration levels will be measured before and after meal consumption in children with PWS, and healthy obese controls. Following an overnight 8 hour fast, subjects will be given either a high carbohydrate or high fat meal. Subjects will be allowed 25 minutes to consume everything on their food tray. Blood samples will be obtained before the meal (fasting) and every 30 minutes thereafter for 4 hours.

Secondary Outcome Measures

Fasting Insulin-like growth factor 1 (IGF-1) levels
Baseline Insulin-like growth factor 1 (IGF-1) levels will be measured fasting before the meal in children with PWS, and healthy obese controls
Neuropeptide Y (NPY)
Baseline Neuropeptide Y (NPY) levels will be measured fasting before the meal in children with PWS, and healthy obese controls
Gastric inhibitory polypeptide (GIP)
Baseline Gastric inhibitory polypeptide (GIP) levels will be measured fasting before the meal in children with PWS, and healthy obese controls
Glucagon-like peptide-1 (GLP-1)
Baseline Glucagon-like peptide-1 (GLP-1) levels will be measured fasting before the meal in children with PWS, and healthy obese controls

Full Information

First Posted
June 1, 2015
Last Updated
August 6, 2015
Sponsor
Duke University
Collaborators
National Institutes of Health (NIH), Canadian Institutes of Health Research (CIHR), Foundation for Prader-Willi Research, Stollery Children's Hospital Foundation, Alberta Diabetes Institute, Sarah W. Stedman Nutrition and Metabolism Center, American Diabetes Association, Duke Children's Miracle Network, National Center for Research Resources (NCRR)
search

1. Study Identification

Unique Protocol Identification Number
NCT02464514
Brief Title
Macronutrient Regulation of Ghrelin and Peptide YY
Official Title
Investigation of the Developmental, Nutritional and Hormonal Regulation of Ghrelin in Children With Prader-Willi Syndrome (PWS) and Children With Hypothalamic-Derived Obesity: Macronutrient Regulation Sub-study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
December 2005 (Actual)
Study Completion Date
December 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
Collaborators
National Institutes of Health (NIH), Canadian Institutes of Health Research (CIHR), Foundation for Prader-Willi Research, Stollery Children's Hospital Foundation, Alberta Diabetes Institute, Sarah W. Stedman Nutrition and Metabolism Center, American Diabetes Association, Duke Children's Miracle Network, National Center for Research Resources (NCRR)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The hyperghrelinemia of children with PWS provides a unique model by which to explore the hormonal and metabolic effects of orexigenic hormones in normal and pathologic conditions. An important question to be addressed by this proposed research includes the macro-nutrient regulation of ghrelin and PYY in obese children and children with PWS. As ghrelin antagonists are considered potential future anti-obesity agents, it is essential to gain understanding of the developmental, nutritional and hormonal regulation of this important orexigenic hormone in children.
Detailed Description
Obesity continues to be a prevalent health concern affecting every race of the American population. Studies show that obese children are likely to become obese adults. Also, recent studies report significant years of life lost due to the impact of being an obese adult . Thus, insights into the pathogenesis of childhood obesity and preventative measures are needed to combat the inevitable increase in worldwide incidence of obesity and its associated co-morbidities. Ghrelin is a 28 amino acid acylated peptide which is an endogenous ligand of the growth hormone secretagogue receptor (GHS-R), a hypothalamic G-protein-coupled receptor. Enteroendocrine cells (X/A-like cells) of the stomach are the major site of ghrelin synthesis, although a minor proportion of ghrelin synthesis occurs in other sites such as the hypothalamus, pituitary, duodenum, jejunum and lung. Secreted in response to meals, ghrelin stimulates feeding through activation of anabolic neurons in the hypothalamic arcuate nucleus that co-express neuropeptide Y (NPY) and agouti-related protein (Agrp). Ghrelin relays its information from the GI tract to specific nuclei in the hypothalamus via the gastric afferent vagal nerve. Studies in rodents support the premise that ghrelin is involved in energy balance. In humans, physiological levels of ghrelin influence energy homeostasis in humans.The rise in plasma ghrelin concentrations during fasting may play a role in meal initiation and body weight regulation. Nearly all other forms of obesity are associated with low ghrelin levels. Paradoxically, researchers discovered that ghrelin levels in adults and children with PWS are 3-5 times higher than those in age- and BMI-matched controls. Hyperghrelinemia may thus play a causal role in the hyperphagia and obesity of PWS. The hyperghrelinemia of children with PWS provides a unique model by which to explore the hormonal and metabolic effects of orexigenic hormones in normal and pathologic condtions. An important question to be addressed by this proposed research includes the macro-nutrient regulation of ghrelin in normal children and children with PWS. As ghrelin antagonists are considered potential future anti-obesity agents, it is essential to gain understanding of the developmental, nutritional and hormonal regulation of this important orexigenic hormone in children.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Prader Willi Syndrome
Keywords
Obesity, Orexigen, Insulin, Leptin, Adiponectin, Growth hormone replacement

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
28 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Healthy obese children
Arm Type
Other
Arm Description
High carbohydrate meal High fat meal
Arm Title
Children with Prader Willi Syndrome
Arm Type
Other
Arm Description
High carbohydrate meal High fat meal
Intervention Type
Other
Intervention Name(s)
High carbohydrate meal
Intervention Description
65% carbohydrate, 17% protein, and 18% fat
Intervention Type
Other
Intervention Name(s)
High fat meal
Intervention Description
58% fat, 17% protein, and 25% carbohydrate
Primary Outcome Measure Information:
Title
Change in ghrelin levels
Description
The change in ghrelin levels will be measured before and after meal consumption in children with PWS, and healthy obese controls. Following an overnight 8 hour fast, subjects will be given either a high carbohydrate or high fat meal. Subjects will be allowed 25 minutes to consume everything on their food tray. Blood samples will be obtained before the meal (fasting) and every 30 minutes thereafter for 4 hours.
Time Frame
4 hours
Title
Change in PYY concentrations
Description
The change in PYY concentration levels will be measured before and after meal consumption in children with PWS, and healthy obese controls. Following an overnight 8 hour fast, subjects will be given either a high carbohydrate or high fat meal. Subjects will be allowed 25 minutes to consume everything on their food tray. Blood samples will be obtained before the meal (fasting) and every 30 minutes thereafter for 4 hours.
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
Fasting Insulin-like growth factor 1 (IGF-1) levels
Description
Baseline Insulin-like growth factor 1 (IGF-1) levels will be measured fasting before the meal in children with PWS, and healthy obese controls
Time Frame
Baseline
Title
Neuropeptide Y (NPY)
Description
Baseline Neuropeptide Y (NPY) levels will be measured fasting before the meal in children with PWS, and healthy obese controls
Time Frame
Baseline
Title
Gastric inhibitory polypeptide (GIP)
Description
Baseline Gastric inhibitory polypeptide (GIP) levels will be measured fasting before the meal in children with PWS, and healthy obese controls
Time Frame
Baseline
Title
Glucagon-like peptide-1 (GLP-1)
Description
Baseline Glucagon-like peptide-1 (GLP-1) levels will be measured fasting before the meal in children with PWS, and healthy obese controls
Time Frame
Baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of PWS confirmed by chromosome analysis (i.e. interstitial deletion of paternally-derived chromosome 15Q, uniparental maternal disomy or other chromosome 15 abnormalities) or normal control Subjects with simple obesity Ages 5 years to 17 years Written informed consent and assent obtained and willingness to comply with the study schedule and procedures. Free T4, TSH values in the normal range (either endogenous or with thyroxine replacement) Exclusion Criteria: Patients with any other clinically significant disease that would have an impact on body composition including diabetes mellitus, chronic inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders Concomitant use of an investigational drug in the past year Patients with an active malignancy Parent or legal guardian unable to provide informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrea Haqq, MD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael Freemark, MD
Organizational Affiliation
Duke University
Official's Role
Study Director
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
26259133
Citation
Gumus Balikcioglu P, Balikcioglu M, Muehlbauer MJ, Purnell JQ, Broadhurst D, Freemark M, Haqq AM. Macronutrient Regulation of Ghrelin and Peptide YY in Pediatric Obesity and Prader-Willi Syndrome. J Clin Endocrinol Metab. 2015 Oct;100(10):3822-31. doi: 10.1210/jc.2015-2503. Epub 2015 Aug 10.
Results Reference
derived

Learn more about this trial

Macronutrient Regulation of Ghrelin and Peptide YY

We'll reach out to this number within 24 hrs